Delcath (NASDAQ: DCTH) is approaching a key catalyst related to its technology Chemosat. The company is slated to hear from the FDA with regards to the acceptance of its NDA for the Chemosat technology and we’ll know whether it’s granted priority review (expected announcement on October 14), or standard review (expected Oct 28). Depending on the […]
INCY – Is It A Good Time To Start A Position?
Incyte Corporation (INCY) The chart of INCY pop up in my chart screener, as a chart with a bullish reversal pattern called “Tripple Bottom” . The Triple Bottom Reversal is a bullish reversal pattern, Once the first bottom is created, the price reaches a peak and retraces back toward the prior support. This is when […]
VRTX – Vertex: Kalydeco Is The Key
Catalyst: North American Cystic Fibrosis Conference, October 11 Outlook: Neutral Ten abstracts from Vertex have been accepted at the North American Cystic Fibrosis Conference (NACFC). Investors will be keenly focused on the October 11 presentation titled, “The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator Ivacaftor Improved CFTR and Lung Function in F508DEL […]
Option traders making moves
Today, we detected some large moves in the option markets for multiple names we follow. As we enter the fourth quarter, we suspect this increase in frequency. ARIAD Pharmaceuticals (NASDAQ: ARIA) The February $16 puts were very active today, with over 9,000 in volume (vs open interest of only 76 contracts). One trader sold two […]
Updates out of ESMO12
The European Society for Medical Oncology (ESMO) Congress 2012 kicked off this weekend and goes until October 2nd(Tuesday). Abstracts with data for those presentations that have already occurred can be viewed and searched here(link). We did get several updates from companies that we would like to review. First up is Threshold Pharmaceuticals (NASDAQ: THLD). On Saturday, they presented […]
PPHM – Little value in Peregrine Pharmaceuticals
For a very brief period of time, Peregrine Pharmaceuticals (NASDAQ: PPHM) had become the phoenix that rose from the ashes. Peregrine recently posted overall survival(OS) data from their randomized Phase II trial in second-line non-small cell lung cancer that excited many. It talked up being approached by over a dozen big pharma companies to partner […]
PPHM – Trade Note #1
Note: Patrick believes there is a risk this trades below $1 prior to OCT expiration if the company comes back with the analysis of what happened or the OS data from the 1st line trial is negative (which he expects) prior to that time.
ZIOP – Analysis of Ziopharma
Biotech investors are currently looking for Ziopharm Oncology (NASDAQ: ZIOP) to announce top-line results of their Phase 3 trial of Palifosfamide. Ziopharm appears close to an inflection point and everyone is awaiting these results. Below we map out the next few months at the company and what to expect. Upcoming events ESMO Presidential Symposium presentation on […]
INFI – Infinity Pharmaceuticals – Is It Overvalued
Catalyst: ASH 2012, December 8-11 Sentiment: Bullish The bulk of Infinity’s value lies in the early stage asset, dual PI3K delta/gamma inhibitor IPI-145. Based on near-term clinical results, Infinity may be deemed vastly overvalued, or the next must-own biotech stock. The company is also developing an HSP90 inhibitor retaspamycin, but we ascribe nominal value to […]
ZIOP – Trading In an Uptrend Channel
Ziopharm(NASDAQ: ZIOP) In Patrick’s latest article “Smallcap Phase 3 data expected by year-end 2012” he mentions Ziopharm’s current Phase 3 trial of Palifosfamide. This Phase 3 trial, known as PICASSO 3, is testing Palifosfamide (Zymafos or ZIO-201) in addition to Doxorubicin versus Doxorubicin in front-line metastatic soft tissue sarcoma. The trial completed enrollment on June 2nd. […]
ACHN – Trade Note #1
Note: Company has an R&D day on Sept 27th and AASLD in early November — both which may increase volatility.
VNDA – A quick review on Vanda’s tasimelteon
After our first quick take on Vanda Pharmaceuticals (NASDAQ: VNDA), we wanted to provide a deeper insight into the development of tasimelteon, the company’s dual MT1/MT2 melatonin receptors agonist. Vanda is expected to report data from two phase III studies by this year’s end in a condition called Non 24-hour sleep wake disorder (N24). Additionally, […]
BMRN – Spotlight on Biomarin
We have talked about BioMarin several times before( #1, #2 and #3). Today, we wanted to put out a brief note on some recent options activity we have noticed. On Friday, we saw some very large options activity that is certainly worth mentioning. The largest trade that happened was a 3-way trade, that does not appear tied […]
INCY – Incyte: Taking The Long View
The pain has not stopped for INCY shareholders since the company offered disappointing revenue guidance in its 2Q conference call August 2. A less than stellar projection of $120 to $135 million in 2012 Jakafi sales did not sit well with investors. This was compounded by the company’s decision to switch mid-year from a sell-through accounting method to […]
Upcoming events for REGN, MDVN, and BMRN
This is the third installment in our series about upcoming events across the biotech sector(be sure to see our 1st piece and 2nd piece). This time around we want to take a look at some upcoming events at some larger biotech companies and what we will be drivers for them going forward. If there are any companies […]
Upcoming events for EXEL, ARQL, CLDX
This is the second installment in our series about upcoming events across the biotech sector(see our 1st piece). As we have said before, this fall should be full of meaningful data catalysts for biotech companies. In our next segment, we will take a look at a few larger biotech companies and what we will be […]
